First results for resetting the antitumor immune response by immune corrective surgery in colon cancer
BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure. METHODS: In this study, we tested the ability of an immune corrective s...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 1998-10, Vol.176 (4), p.339-343 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 343 |
|---|---|
| container_issue | 4 |
| container_start_page | 339 |
| container_title | The American journal of surgery |
| container_volume | 176 |
| creator | Barbera-Guillem, Emilio Arnold, Mark W Nelson, M.Bud Martin, Edward W |
| description | BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure.
METHODS:
In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved in TAG-72 presentation. By removing these lymph nodes, together with the tumor tissue, presentation and source of TAG-72 are drastically reduced.
RESULTS:
The impact of this TAA suppression on the tumor recurrence process is analyzed in a sample of 24 patients. The immune corrective surgical procedure did not increase morbidity. Five years after surgery the following were disease free: 5 of 5 stage I, 6 of 6 stage II, and 10 of 13 stage III. The global survival of this group was 87.5%. Compared with the standard surgical treatment of colon cancer (58% survival for the same stages), this surgical immune corrective procedure introduces a statistically significant improvement of 29% (
P |
| doi_str_mv | 10.1016/S0002-9610(98)00192-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70057224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961098001925</els_id><sourcerecordid>2847459050</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-abf167b429d1cf6a04ec98fe6ba84622a49d7d12dd059dcd344f68d65cf1c1da3</originalsourceid><addsrcrecordid>eNqFkU9rFTEUxUNR6rP2IxQGKqKL0SSTZJJVkWJVKLjQrkMmuakpM5PXJFPotzfT99pCN27y557fPVzOReiE4M8EE_HlN8aYtkoQ_FHJTxgTRVt-gDZE9qolUnav0OYJeYPe5nxTv4Sw7hAdKkl6yskG-YuQcmkS5GUsufExrW8oJczXTfkLjZlLKMtU62GalhlWeRvnDM1w_1iyMSWwJdxBk5d0Dakqc62OsZ5mtpDeodfejBmO9_cRurr49uf8R3v56_vP86-XrWVCldYMnoh-YFQ5Yr0wmIFV0oMYjGSCUsOU6x2hzmGunHUdY15IJ7j1xBJnuiP0Yee7TfF2gVz0FLKFcTQzxCXrHmPeU8oqePoCvIlLmutsmkrWM64wx5XiO8qmmHMCr7cpTCbda4L1ugX9sAW9RqyV1A9b0Lz2nezdl2EC99S1j73q7_e6ydaMPtWQQn4251Jx1lXsbIdBjewuQNLZBqh5urDmrV0M_xnkHyf1pUc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2847459050</pqid></control><display><type>article</type><title>First results for resetting the antitumor immune response by immune corrective surgery in colon cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Barbera-Guillem, Emilio ; Arnold, Mark W ; Nelson, M.Bud ; Martin, Edward W</creator><creatorcontrib>Barbera-Guillem, Emilio ; Arnold, Mark W ; Nelson, M.Bud ; Martin, Edward W</creatorcontrib><description>BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure.
METHODS:
In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved in TAG-72 presentation. By removing these lymph nodes, together with the tumor tissue, presentation and source of TAG-72 are drastically reduced.
RESULTS:
The impact of this TAA suppression on the tumor recurrence process is analyzed in a sample of 24 patients. The immune corrective surgical procedure did not increase morbidity. Five years after surgery the following were disease free: 5 of 5 stage I, 6 of 6 stage II, and 10 of 13 stage III. The global survival of this group was 87.5%. Compared with the standard surgical treatment of colon cancer (58% survival for the same stages), this surgical immune corrective procedure introduces a statistically significant improvement of 29% (
P <0.001).
CONCLUSIONS:
The surgical removal of lymph nodes involved in the persistent humoral immune response against TAA has an important beneficial impact on colon cancer treatment.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/S0002-9610(98)00192-5</identifier><identifier>PMID: 9817251</identifier><identifier>CODEN: AJSUAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Antibodies ; Antibodies, Neoplasm - immunology ; Antibody Formation ; Antigen (tumor-associated) ; Antigen Presentation - immunology ; Antigen-antibody complexes ; Antigens ; Antigens, Neoplasm - immunology ; Antitumor activity ; Biological and medical sciences ; Cancer ; Cancer therapies ; Chemotherapy ; Colon cancer ; Colonic Neoplasms - immunology ; Colonic Neoplasms - pathology ; Colonic Neoplasms - therapy ; Colorectal cancer ; Coronary vessels ; Dendritic cells ; Gastroenterology. Liver. Pancreas. Abdomen ; Hospitals ; Humans ; Immune response ; Immune response (cell-mediated) ; Immune response (humoral) ; Immune system ; Immunotherapy ; Lymph Node Excision ; Lymph nodes ; Lymph Nodes - immunology ; Lymphatic system ; Medical research ; Medical sciences ; Mesentery ; Metastasis ; Morbidity ; Mortality ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Patients ; Prognosis ; Prospective Studies ; Radioimmunodetection ; Statistical analysis ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Surgeons ; Surgery ; Survival ; Survival Analysis ; Treatment Outcome ; Tumors</subject><ispartof>The American journal of surgery, 1998-10, Vol.176 (4), p.339-343</ispartof><rights>1998 Excerpta Medica Inc.</rights><rights>1999 INIST-CNRS</rights><rights>1998. Excerpta Medica Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-abf167b429d1cf6a04ec98fe6ba84622a49d7d12dd059dcd344f68d65cf1c1da3</citedby><cites>FETCH-LOGICAL-c469t-abf167b429d1cf6a04ec98fe6ba84622a49d7d12dd059dcd344f68d65cf1c1da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2847459050?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1589543$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9817251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barbera-Guillem, Emilio</creatorcontrib><creatorcontrib>Arnold, Mark W</creatorcontrib><creatorcontrib>Nelson, M.Bud</creatorcontrib><creatorcontrib>Martin, Edward W</creatorcontrib><title>First results for resetting the antitumor immune response by immune corrective surgery in colon cancer</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure.
METHODS:
In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved in TAG-72 presentation. By removing these lymph nodes, together with the tumor tissue, presentation and source of TAG-72 are drastically reduced.
RESULTS:
The impact of this TAA suppression on the tumor recurrence process is analyzed in a sample of 24 patients. The immune corrective surgical procedure did not increase morbidity. Five years after surgery the following were disease free: 5 of 5 stage I, 6 of 6 stage II, and 10 of 13 stage III. The global survival of this group was 87.5%. Compared with the standard surgical treatment of colon cancer (58% survival for the same stages), this surgical immune corrective procedure introduces a statistically significant improvement of 29% (
P <0.001).
CONCLUSIONS:
The surgical removal of lymph nodes involved in the persistent humoral immune response against TAA has an important beneficial impact on colon cancer treatment.</description><subject>Antibodies</subject><subject>Antibodies, Neoplasm - immunology</subject><subject>Antibody Formation</subject><subject>Antigen (tumor-associated)</subject><subject>Antigen Presentation - immunology</subject><subject>Antigen-antibody complexes</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antitumor activity</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - immunology</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - therapy</subject><subject>Colorectal cancer</subject><subject>Coronary vessels</subject><subject>Dendritic cells</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune response (cell-mediated)</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Lymph Node Excision</subject><subject>Lymph nodes</subject><subject>Lymph Nodes - immunology</subject><subject>Lymphatic system</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mesentery</subject><subject>Metastasis</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Radioimmunodetection</subject><subject>Statistical analysis</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Surgeons</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU9rFTEUxUNR6rP2IxQGKqKL0SSTZJJVkWJVKLjQrkMmuakpM5PXJFPotzfT99pCN27y557fPVzOReiE4M8EE_HlN8aYtkoQ_FHJTxgTRVt-gDZE9qolUnav0OYJeYPe5nxTv4Sw7hAdKkl6yskG-YuQcmkS5GUsufExrW8oJczXTfkLjZlLKMtU62GalhlWeRvnDM1w_1iyMSWwJdxBk5d0Dakqc62OsZ5mtpDeodfejBmO9_cRurr49uf8R3v56_vP86-XrWVCldYMnoh-YFQ5Yr0wmIFV0oMYjGSCUsOU6x2hzmGunHUdY15IJ7j1xBJnuiP0Yee7TfF2gVz0FLKFcTQzxCXrHmPeU8oqePoCvIlLmutsmkrWM64wx5XiO8qmmHMCr7cpTCbda4L1ugX9sAW9RqyV1A9b0Lz2nezdl2EC99S1j73q7_e6ydaMPtWQQn4251Jx1lXsbIdBjewuQNLZBqh5urDmrV0M_xnkHyf1pUc</recordid><startdate>19981001</startdate><enddate>19981001</enddate><creator>Barbera-Guillem, Emilio</creator><creator>Arnold, Mark W</creator><creator>Nelson, M.Bud</creator><creator>Martin, Edward W</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19981001</creationdate><title>First results for resetting the antitumor immune response by immune corrective surgery in colon cancer</title><author>Barbera-Guillem, Emilio ; Arnold, Mark W ; Nelson, M.Bud ; Martin, Edward W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-abf167b429d1cf6a04ec98fe6ba84622a49d7d12dd059dcd344f68d65cf1c1da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Antibodies</topic><topic>Antibodies, Neoplasm - immunology</topic><topic>Antibody Formation</topic><topic>Antigen (tumor-associated)</topic><topic>Antigen Presentation - immunology</topic><topic>Antigen-antibody complexes</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antitumor activity</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - immunology</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - therapy</topic><topic>Colorectal cancer</topic><topic>Coronary vessels</topic><topic>Dendritic cells</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune response (cell-mediated)</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Lymph Node Excision</topic><topic>Lymph nodes</topic><topic>Lymph Nodes - immunology</topic><topic>Lymphatic system</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mesentery</topic><topic>Metastasis</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Radioimmunodetection</topic><topic>Statistical analysis</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Surgeons</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barbera-Guillem, Emilio</creatorcontrib><creatorcontrib>Arnold, Mark W</creatorcontrib><creatorcontrib>Nelson, M.Bud</creatorcontrib><creatorcontrib>Martin, Edward W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barbera-Guillem, Emilio</au><au>Arnold, Mark W</au><au>Nelson, M.Bud</au><au>Martin, Edward W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First results for resetting the antitumor immune response by immune corrective surgery in colon cancer</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>1998-10-01</date><risdate>1998</risdate><volume>176</volume><issue>4</issue><spage>339</spage><epage>343</epage><pages>339-343</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><coden>AJSUAB</coden><abstract>BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure.
METHODS:
In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved in TAG-72 presentation. By removing these lymph nodes, together with the tumor tissue, presentation and source of TAG-72 are drastically reduced.
RESULTS:
The impact of this TAA suppression on the tumor recurrence process is analyzed in a sample of 24 patients. The immune corrective surgical procedure did not increase morbidity. Five years after surgery the following were disease free: 5 of 5 stage I, 6 of 6 stage II, and 10 of 13 stage III. The global survival of this group was 87.5%. Compared with the standard surgical treatment of colon cancer (58% survival for the same stages), this surgical immune corrective procedure introduces a statistically significant improvement of 29% (
P <0.001).
CONCLUSIONS:
The surgical removal of lymph nodes involved in the persistent humoral immune response against TAA has an important beneficial impact on colon cancer treatment.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9817251</pmid><doi>10.1016/S0002-9610(98)00192-5</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 1998-10, Vol.176 (4), p.339-343 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70057224 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Antibodies Antibodies, Neoplasm - immunology Antibody Formation Antigen (tumor-associated) Antigen Presentation - immunology Antigen-antibody complexes Antigens Antigens, Neoplasm - immunology Antitumor activity Biological and medical sciences Cancer Cancer therapies Chemotherapy Colon cancer Colonic Neoplasms - immunology Colonic Neoplasms - pathology Colonic Neoplasms - therapy Colorectal cancer Coronary vessels Dendritic cells Gastroenterology. Liver. Pancreas. Abdomen Hospitals Humans Immune response Immune response (cell-mediated) Immune response (humoral) Immune system Immunotherapy Lymph Node Excision Lymph nodes Lymph Nodes - immunology Lymphatic system Medical research Medical sciences Mesentery Metastasis Morbidity Mortality Neoplasm Recurrence, Local Neoplasm Staging Patients Prognosis Prospective Studies Radioimmunodetection Statistical analysis Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Surgeons Surgery Survival Survival Analysis Treatment Outcome Tumors |
| title | First results for resetting the antitumor immune response by immune corrective surgery in colon cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A46%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20results%20for%20resetting%20the%20antitumor%20immune%20response%20by%20immune%20corrective%20surgery%20in%20colon%20cancer&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Barbera-Guillem,%20Emilio&rft.date=1998-10-01&rft.volume=176&rft.issue=4&rft.spage=339&rft.epage=343&rft.pages=339-343&rft.issn=0002-9610&rft.eissn=1879-1883&rft.coden=AJSUAB&rft_id=info:doi/10.1016/S0002-9610(98)00192-5&rft_dat=%3Cproquest_cross%3E2847459050%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2847459050&rft_id=info:pmid/9817251&rft_els_id=S0002961098001925&rfr_iscdi=true |